Licensing deals might be pharma’s preferred mode of business development these days—perhaps even more so than outright acquisitions.
Punnett squares and phenotypes, chromatids and codominance: genetics, and all of its associated terms, isn’t the easiest field to understand....
Drugs with low oral bioavailability risk failure in clinical trial: minimal absorption, after all, can translate to reduced efficacy. As...
The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute.
Artificial intelligence is revolutionizing technology, but also medicine. Here’s how.
What exactly are mesenchymal stem cells … and more importantly, why should investors care?
Herceptin, Enbrel, Botox: at first glance, these therapies may appear to have little in common.
When generic competitors enter the market, sales from a blockbuster drug can decrease significantly.
From serums and masks to oral sprays and enriched waters, we’re counting down the novel ways in which some cannabis-based...
The body already has amazing regenerative abilities—can we not harness that power and, in turn, amplify it?